University Health Network, Toronto General Hospital, Ajmera Transplant Centre
Toronto, Ontario, M5G 2N2, Canada
NCT Number: NCT07488481
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Early Phase 1
Toronto, Ontario, M5G 2N2, Canada
Cytomegalovirus (CMV) is the most common viral infection in transplant recipients and has major impacts on patient outcomes. It can cause fever, pneumonia, gastrointestinal disease, and lead to rejection of the kidney. To prevent this, transplant recipients receive prolonged antiviral drugs. This leads to significant drug toxicity and cost, and is often not successful. The risk of CMV is much higher if the donor organ carries latent CMV inside it (approximately 50-70% of donor organs). A much better and safer strategy would therefore be to try to eliminate the latent virus from the donor organ prior to transplantation. Ex Vivo Organ Perfusion (EVOP) is a common method of donor organ preservation and treatment which allows donor organs to be treated for several hours under close to physiological conditions.
The investigators propose a study in which kidneys will be treated prior to transplantation on the EVOP platform in order to decrease latent CMV. SYN002 is a novel compound that binds to cells that are latently infected with CMV and is internalized and kills those specific cells. This pilot study will involve 12 kidney transplant patients, who are receiving a kidney known to have latent CMV. The kidney will be treated with SYN002 on the EVOP system prior to transplantation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Recipient Inclusion Criteria:
Recipient Exclusion Criteria:
Donor Inclusion Criteria:
Donor Exclusion Criteria:
SYN002, a fusion protein targeting US28, a human cytomegalovirus (CMV) - specific virally encoded receptor expressed on both latent and lytic CMV-infected cells.
Time frame: 4 weeks post-transplant
Proportion of patients with a functioning graft at 4 weeks post-transplant defined as no longer needing dialysis at 4 weeks
Time frame: 4 weeks post-transplant
a. Proportion of patients with delayed graft function with requirement for dialysis post-transplant
Time frame: 3 months post-transplant
Proportion of patients that develop CMV DNAemia with plasma viral load > 1000 IU/ml at 3 months post-transplant
Time frame: 6 months post-transplant
Median days of hospital stay
Time frame: 3 months post-transplant
Proportion of patients with a functioning graft
Time frame: 6 months
Proportion of patients with a functioning graft
Time frame: 6 months post-transplant
Proportion of patients that develop CMV DNAemia with plasma viral load > 1000 IU/ml at 6 months post-transplant
Time frame: 6 months post-transplant
Proportion of patients with CMV disease
Contact information is provided by the study sponsor or research team.
University Health Network, Toronto
Other
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission: A Safety Trial in Kidney Transplant Recipients
Acronym: RESPECT-CMV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07379203
Cytomegalovirus (CMV) Infection, Cytomegalovirus Infections
View Trial DetailsNCT07009548
Cytomegalovirus (CMV) Infection, Cytomegalovirus Infections
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT03940586
Cytomegalovirus (CMV) Infection, Cytomegalovirus Infections
Duarte, California, United States
View Trial DetailsNCT03629080
Cytomegalovirus (CMV) Infection, Cytomegalovirus Infections
Birmingham, Alabama, United States
View Trial Details